Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | HTR2C | P28335 | 7/20 | 0.39 |
| ▸ | HTR2B | P41595 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2369504 | 0.99 | HTR2A (0.38) | HTR2AHTR2CHTR2BLMNASMN1; SMN2 | |
| SCHEMBL507548 | 0.77 | HTR2A (0.39) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL2369502 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL11948262 | 0.69 | HTR2A (0.47) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL10229189 | 0.69 | HTR2A (0.49) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL10229157 | 0.68 | HTR2A (0.40) | HTR2AHTR2CHTR2BLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4398181 | 0.68 | APOBEC3A (0.36) | HTR2AHTR2CHTR2BLMNAPNMT | |
| Hydrochloric Acid SCHEMBL508195 | 0.68 | HTR2A (0.48) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL10476355 | 0.68 | HTR2B (0.48) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL10476177 | 0.68 | HTR2B (0.48) | HTR2AHTR2CHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | HTR2A 4/4885HTR2C 1/4885HTR2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.